REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Enzyme Or Coenzyme Containing > Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) > Acting On Glycosyl Compound (3.2) (e.g., Glycosidases Lysozyme, Nucleosidases, Cellulase, Etc.) Acting On Glycosyl Compound (3.2) (e.g., Glycosidases Lysozyme, Nucleosidases, Cellulase, Etc.)Acting On Glycosyl Compound (3.2) (e.g., Glycosidases Lysozyme, Nucleosidases, Cellulase, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178081 - Combination therapy for treating protein deficiency disorders This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides stable compositions comprising the purified protein and an ASSC, and methods of treatment by administering the ... 07/12/07 - 20070160593 - Sugar chain-cleaving agent A sugar chain-cleaving agent, which comprises a protein having activity of degrading chondroitin and/or chondroitin sulfate; a medicament which comprises the sugar chain-cleaving agent as an active ingredient; a method for specifically cleaving a sugar chain, which comprises reacting the protein with chondroitin and/or chondroitin sulfate; and a method for ... 06/28/07 - 20070148158 - Rationally designed heparinases derived from heparinase ii Modified heparinases having altered binding specificity and activity are provided. Isolated nucleic acids encoding the same as well as vectors and host cells are provided. Methods for using the modified heparinases are also provided. ... 06/28/07 - 20070148157 - Chondroitinase abc i polynucleotides The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans ... 06/28/07 - 20070148156 - Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof The invention relates to the discovery of a novel Chondroitinase Glycoproteins (CHASEGP's), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal ... 06/21/07 - 20070141041 - Enzymes for reduced immunological stress Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as ... 06/14/07 - 20070134228 - Human plasma hyaluronidase The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification methods The method of immunoaffinity purification of the invention is based on the discovery of a method for identifying antibodies that specifically bind ... 06/14/07 - 20070134227 - Catalyst for cleaving sugar chain A catalyst which is capable of specifically cleaving one sugar chain or two or more sugar chains selected from the group consisting of hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C and chondroitin sulfate D; a cleavage agent specific for the sugar chains; a medicament which is used for specifically ... 06/07/07 - 20070128180 - Galactanase variants Variants of Glycoside Hydrolase family 53 galactanases, e.g. variants of the galactanases from strains of Yersinia, Aspergillus, Humicola, Meripilus, Myceliophthora, Thermomyces, Bacillus, Bifidobacterium, Cellvibrio, Clostridium, Pseudomonas, Thermotoga, or Xanthomonas. ... 05/24/07 - 20070116698 - Novel methods and medicament for treating infectious diseases involving microbial biofilms The present invention provides a method for prophylaxis and therapy of infectious diseases caused by microorganisms present in biofilms adherent to cell surfaces comprising the step of administering to an individual in need thereof a composition comprising a combination of at least one compound chosen from the group of peroxidase, ... 05/24/07 - 20070116697 - Nanosphere/microsphere delivery system for the treatment of spinal cord injury A formulation including injectable biodegradable nanospheres and/or microspheres as a delivery system for chondroitinase ABC (cABC) or a functional derivative of cABC to treat acute and chronic spinal chord injury in a mammal having the same is provided. The biodegradable nanosphere/microsphere formulation releases cABC or a functional derivative of cABC ... 05/10/07 - 20070104703 - Compositions and methods of using chondroitinase abci mutants One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided. ... 05/03/07 - 20070098708 - Heparan sulfate glycosaminoglycan lyase and uses thereof The invention provides recombinant B. thetaiotaomicron HSGAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron HSGAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the ... 04/12/07 - 20070081986 - Beta-glucuronidase with an attached short peptide of acidic amino acids Disclosed are a fusion protein comprising enzyme β-glucuronidase and short peptide consisting 4-15 acidic amino acids attached to the enzyme on its N-terminal side, pharmaceutical composition containing the fusion protein, and a method for treatment of type VII mucopolysaccharidosis using the fusion protein. Compared with the native enzyme, the fusion ... 04/12/07 - 20070081985 - Lysozyme fortified milk and milk products Milk and/or yogurt fortified with lysozyme for augmentation of the immune system and aid the immune compromised. ... 03/22/07 - 20070065424 - Rationally designed polysaccharide lyases derived from chondroitinase b The invention relates to rationally designed polysaccharide lyases and uses thereof. In particular, the invention relates to modified chondroitinase B. The modified chondroitinase B enzymes of the invention are useful for a variety of purposes, including cleaving and sequencing polysaccharides such as glycosaminoglycans (GAGs) as well as removing polysaccharides from ... 02/08/07 - 20070031397 - Compositions and methods for enhancing axon regeneration As described below, the present invention generally features compositions and methods for the treatment of CNS disease or injury. In particular, the invention provides methods and compositions for enhancing axonal outgrowth in a subject. In one embodiment, the invention enhances the success of CNS restorative surgery. ... 01/04/07 - 20070003538 - Antimicrobial compositions and uses thereof The present invention provides compositions for preventing growth and proliferation of biofilm embedded microorganisms on devices comprising: (a) a cationic polypeptide and (b) a bis-gaunide or a salt thereof. The invention further provides methods for preparing medical devices withy such compositions. ... 12/21/06 - 20060286087 - Recombinant alpha-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof The present invention provides a recombinant α-L-iduronidase and biologically active fragments and mutants thereof, methods to produce and purify this enzyme as well as methods to treat certain genetic disorders including—α-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1). ... 12/21/06 - 20060286086 - Lysozyme-based food stuff Homogenized, semi-solid food stuff fortified with lysozyme for augmentation of the immune system and to aid the immune compromised. ... 11/16/06 - 20060257388 - Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction ... 11/16/06 - 20060257387 - Sugar chain synthase gene The present invention provides a method effective for diagnosis or treatment of congenital disorders of glycosylation syndrome (CDGS) by clarifying the gene of the N-linked sugar chain synthase in human endoplasmic reticulum. In the present invention, a gene of an enzyme catalyzing human N-linked sugar chain synthesis is found based ... 11/09/06 - 20060251641 - Method and apparatus for treatment of cardiac disorders The present invention is directed to systems and methods for delivering therapy for a cardiac disorder, wherein the system comprises a source for supplying a protein formulation containing a protein that is otherwise deficient in cardiac cells in a patient with a cardiac disorder, and a catheter having a proximal ... 11/02/06 - 20060246049 - Compositions and methods for enzymatic detachment of bacterial and fungal biofilms Isolated nucleic acid sequences and amino acid sequences for soluble, β-N-acetylglucosaminidase or active fragments or variants thereof which promote detachment of bacterial cells from a biofilm are provided. An isolated mutant bacteria which forms biofilm colonies which tightly adhere to surface but which are unable to release cells into the ... 10/26/06 - 20060239992 - Methods and compositions for the inhibition of growth of infectious aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species A method for the prevention and treatment of fungal infections and, therefore, consequent invasive mycosis in mammalian and avian species is described. The invention comprise a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)glucan, diatomaceous earth, mineral clay, and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient ... 10/19/06 - 20060233782 - Proteoglycan degrading mutants for the treatment of cns The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease. ... 10/19/06 - 20060233781 - Antimicrobial composition for local use on mucosal membranes and skin The invention relates to an antimicrobial composition for local use on mucosal membranes and skin. The antimicrobial composition comprises a system of lysozyme and glycosylated immunoglobulins. The glycosylated immunoglobulins have affinity towards gram negative and gram positive bacteria and viruses. Moreover, the invention concerns the method of preparation of said ... 10/12/06 - 20060228348 - Targeting of glycoprotein therapeutics Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In ... 09/28/06 - 20060216281 - Process for producing aglycon and flavor-improved food containing the aglycon by diglycosidase, and converting agent to be used in the process A physiologically active substance of aglycon type, in particular, aglycon isoflavone, can be efficiently produced, without resort to any acid/alkali treatment or fermentation and substantially without changing the physical properties of a material, by treating the material with a sufficient amount of diglycosidase for a sufficient period of time at ... 09/14/06 - 20060204487 - Production of high mannose proteins in plant culture A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes ... 09/07/06 - 20060198833 - Compositions and methods for targeting a polypeptide to the central nervous system The invention provides a chimeric CNS targeting polypeptide having a BBB-receptor binding domain and a payload polypeptide domain. The chimeric CNS targeting polypeptide can have a BBB-receptor binding domain consisting of a receptor binding domain from ApoB, ApoE, aprotinin, lipoprotein lipase, PAI-1, pseudomonas exotoxin A, transferrin, α2-macroglobulin, insulin-like growth factor, ... 08/31/06 - 20060193845 - Combination therapy for controlled carbohydrate digestion Carbohydrate usage in the gastro-intestinal tract of a subject can be modulated by administering, to a subject, a first agent that inhibits carbohydrate degradation in combination with a second agent that decreases formation or severity of intestinal gas. ... 08/17/06 - 20060182734 - Methods for preparing low molecular weight heparin with modified heparinase iii The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. ... 08/10/06 - 20060177433 - Treatment of alpha-galactosidase a deficiency The invention provides methods of treating α-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human α-galactosidase A are also included. ... 07/27/06 - 20060165674 - Granular composition and process for producing the same The present invention intends to provide a granular composition which is stable at high temperature and high humidity and to provide a simple method of efficiently producing such a granular composition. According to the present invention, there is provided a granular composition containing a core material and a layer that ... 07/27/06 - 20060165673 - Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same 3-OST-5 proteins, and nucleic acid molecules encoding the same. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed, along with methods of producing each. Isolated and purified antibodies to 3-OST-5 homologs, and methods of producing the same, are also disclosed. 3OST-5 gene products have biological activity in ... 07/20/06 - 20060159671 - Uses of sysnergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections Methods for treating and preventing bacterial infections are described using at least two lytic enzymes obtained from a bacteriophage isolated from Streptococci. Two of these enzymes, Pal and Cpl-1, showed synergy when tested for cleavage of peptidoglycan in the cell walls of Streptococcus pneumoniae. Moreover, the combination of these two ... 07/13/06 - 20060153826 - Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and to its application for genome engineering and gene therapy. ... 07/06/06 - 20060147442 - Biocides The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification). ... 06/29/06 - 20060140928 - Use of heparinases to decrease inflammatory response Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized ... 06/22/06 - 20060134091 - Additive for an animal feed The present invention relates to the use of a combination of a protease and an inner salt of a quaternary amine carboxylic acid for the preparation of an agent for the treatment and/or prophylaxis of coccidiosis and bacterial infections such as necrotic enterities in animals. Preferred embodiments of the invention ... 06/08/06 - 20060121019 - Compositions for treating cystic fibrosis A composition for degrading biofilm structure associated with cystic fibrosis and the debris associated therewith comprises an enzyme selected for its ability to dismantle the biofilm structure, and an anchor molecule coupled to an enzyme to form an enzyme-anchor complex. The anchor molecule is selected for its ability to attach ... 06/08/06 - 20060121018 - Methods and compositions for targeting proteins across the blood brain barrier Disclosed are methods and compositions for targeting therapeutic proteins to the brain. Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain. Soluble fusion proteins that include an IGF targeting moiety are transported to neural ... 06/01/06 - 20060115468 - Dietary supplement for treating and preventing gastrointestinal disorders A dietary and vitamin supplement, in capsule or powder form, for enhancing and maintaining digestive health and colon care, and alleviating gastrointestinal disorders, includes a blend of natural ingredients, including acidophilus, digestive enzymes and antioxidants, and which can be taken on an as-needed basis, in either capsule or liquid form, ... 05/18/06 - 20060104968 - Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties ... 04/27/06 - 20060088517 - Compounds and methods for treating seizure disorders This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells. ... 04/20/06 - 20060083732 - Hyaluronic acid in the enhancement of lens regeneration The present invention addresses the treatment of ocular conditions by the enhancement of lens regeneration. This is accomplished by the administration of a high viscosity composition including a hyaluronic acid compound. Excess high viscosity composition may be removed by focal laser photophacoablation or through the use of a digestive compound ... 04/20/06 - 20060083731 - Use of an enzyme for the manufacture of an agent for controlling bacterial infection Xylanase or a cellulase for the manufacture of an agent for the treatment and/or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens. It is preferred that xylanase is used in combination with wheat to form an animal feed. Such a diet is particularly effective ... 03/30/06 - 20060067928 - Heparinase iii and methods of specifically cleaving therewith The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis , etc. have been discovered according to the ... 03/30/06 - 20060067927 - Methods and compositions related to the modulation of intercellular junctions The invention relates to compositions and methods for the modulation of the permeability of the epithelial cell barrier complex. In particular, the invention provides compositions and methods for using polysaccharides, preferably glycosaminoglycans, and agents that modify cell surface glycosaminoglycans, preferably glycosaminoglycan-degrading enzymes to modulate intercellular junctions. The compositions and methods ... 03/02/06 - 20060045874 - Aminoglycoside treatment for lysosomal storage diseases The present invention provides a method of treating lysosomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically effective dose of an aminoglycoside. In addition, this method may further comprise treating the individual ... 02/16/06 - 20060034821 - Methods and compositions for treating neoplasms The present invention comprises the periodic administration of a solution of neuraminidase to a patient with a neoplasm until the neoplasm has receded. The administration of the solution of neuraminidase can be administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration. The present invention ... 02/16/06 - 20060034820 - Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof. ... 02/02/06 - 20060024288 - Trna synthetase fragments The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and ... 02/02/06 - 20060024287 - Compositions and methods for modulating angiogenesis The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to variants of tRNA synthetase fragments, or more preferably tryptophanyl tRNA synthetase fragments, or more preferably human tryptophanyl tRNA synthetase fragments. ... 02/02/06 - 20060024286 - Variants of trna synthetase fragments and uses thereof The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to variants of tRNA synthetase fragments, or more preferably tryptophanyl tRNA synthetase fragments, or more preferably human tryptophanyl tRNA synthetase fragments. ... 01/19/06 - 20060013807 - Rapidly disintegrating enzyme-containing solid oral dosage compositions The present invention relates to rapidly disintegrating solid oral dosage forms having an effective amount of an enzyme and a superdisintegrant. ... 12/29/05 - 20050287134 - Drug delivery system for accelerated subcutaneous absorption A method for accelerating subcutaneous absorption of a fluid or drug into the systemic circulation of a specific targeted tissue. A first drug operative to produce local capillary vasodilatation and/or increase the rate of bulk flow of solution through the interstitial space is mixed with a fluid. The fluid may ... 12/22/05 - 20050281805 - Targeted therapeutic proteins Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. ... 12/22/05 - 20050281804 - Methods of treating diseases caused by deficiencies of recombinant alpha-l-iduronidase The present invention provides a formulation comprising a pharmaceutical composition comprising a human recombinant α-L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a pharmaceutically acceptable carrier. The present invention further provides methods to treat certain genetic disorders including α-L-iduronidase deficiency ... 12/08/05 - 20050271645 - Intratracheal administration of lysozyme with other therapeutic agents in the prevention and treatment of respiratory disorders The subject invention is directed to the prevention and treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme, either alone or in combination with other therapeutic agents. Applicable respiratory disorders include, but are not limited to, pulmonary emphysema, asthma, bronchitis, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, ... 12/01/05 - 20050265988 - Glycosylated glucocerebrosidase expression in fungal hosts A recombinant fungal host cell producing recombinant glucocerebrosidase is provided. A functional recombinant glucocerebrosidase produced in recombinant fungal host cells is also provided. Methods for producing and isolating functional recombinant glucocerebrosidase from fungal hosts are also provided. ... 12/01/05 - 20050265987 - Sulfatases and methods of use thereof Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of ... 11/24/05 - 20050260187 - Therapeutic and cosmetic uses of heparanases Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed. ... 11/24/05 - 20050260186 - Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties ... 11/24/05 - 20050260185 - Methods for treating diseases caused by deficiencies of recombinant alpha-l-iduronidase The present invention provides a formulation comprising a pharmaceutical composition comprising a human recombinant α-L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a pharmaceutically acceptable carrier. The present invention further provides methods to treat certain genetic disorders including α-L-iduronidase deficiency ... 11/10/05 - 20050249718 - Compositions and methods for treating disorders associated with abnormal phosphate metabolism The present invention uncovers that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause familial tumoral calcinosis (FTC). Methods and pharmaceutical compositions useful for treating disorders associated with abnormal phosphate metabolism are provided. Specifically, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on ... 11/10/05 - 20050249717 - Use of hyaluronidase for preventing and treating cardio vascular diseases The invention relates to use of the enzyme hyaluronidase in a dosage of at least 6,000 units per day for prevention and/or treatment of cardiovascular diseases whereby the hyaluronidase is administered intra venam over a period of at least four weeks. Hyaluronidase is particularly suited to treating coronary heart diseases ... 11/03/05 - 20050244400 - Acid alpha-glucosidase and fragments thereof Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, ... 11/03/05 - 20050244399 - Materials and method for promotion of nerve regeneration The subject invention pertains to the therapeutic use of certain GAG-degrading enzymes, and enzyme combinations, to promote nerve repair and regeneration. ... 09/29/05 - 20050214276 - Delta 4, 5 glycuronidase and uses thereof The invention relates to Δ4,5 glycuronidase, related compositions, and methods of use thereof. ... 09/08/05 - 20050196392 - Lesion repair polymerase compositions Compositions comprising at least two polymerases, including a lesion repair polymerase, are provided. Methods for producing primer extension products using at least two polymerases, including a lesion repair polymerase, are also provided. Kits for producing primer extension products comprising at least two polymerases, including a lesion repair polymerase, are also ... 09/01/05 - 20050191288 - Use of heparinase to decrease inflammatory responses Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized ... 08/18/05 - 20050180965 - Heat-reversible composition treating hyposalia and asialia A heat-reversible composition designed to compensate salivary deficiencies, includes at least a polymeric compound whose viscosity is low at room temperature and which increases at oral temperature so as to reach optimal viscosity at oral temperature to gelling point. ... 08/18/05 - 20050180964 - Methods and compositions for the inhibition of growth of infectious aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species A method for the prevention and treatment of fungal infections and, therefore, consequent invasive mycosis in mammalian and avian species is described. The invention comprises a combination of β-1,3(4)-endoglucanohydrolase, β-1,3(4)glucan, diatornaceous earth, mineral clay, and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient ... 08/04/05 - 20050169907 - Substances directed against a specific sequence essential for heparanase catalytic activity and uses thereof as heparanase inhibitors An amino acid sequence derived from the N′ terminus region of the 50 Kd subunit of heparanase, preferably, the sequence including amino acid residues Lys158-Asn171 of human heparanase and any functional fragments thereof. Compositions for the inhibition of heparanase glycosidase catalytic activity, having as an active ingredient an isolated and ... 06/09/05 - 20050123531 - Treatment of glycogen storage disease type ii Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. ... 06/02/05 - 20050118158 - Pharmacological vitreolysis A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, ... 06/02/05 - 20050118157 - Treatment of central nervous system damage The invention provides a method of promoting neuronal plasticity in the CNS of a mammal, the method comprising administering to the CNS of the mammal an agent that reduces the inhibitory properties of chondroitin sulphate proteoglycans. Preferred agents are chondroitinases and sulfatases, e.g., chondroitinase ABC. Also provided are methods of ... ### FreshPatents.com Support |